Earli
holds a patent for "methods and compositions for synthetic biomarkers" and presented early-cancer-detection data at AACR annual meetings and in Nature Communications, engineering constructs that localize to tumor tissue and amplify an otherwise sub-detectable signal.
- Country
- United States
Growth
Synthetic biomarker gene circuits
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaema
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Synthetic biomarkers | diagnostics-medtech | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.